8-KOther EventsExhibits & Filings

PFIZER INC 8-K Report, Corporate Update (Mar 2, 2017)

Filed March 2, 2017For Securities:PFE

Summary

Pfizer Inc. (PFE) filed an 8-K on March 2, 2017, reporting on a significant debt financing transaction that occurred on February 28, 2017. The company successfully priced a public offering of notes totaling €4,000,000,000 across several tranches with varying interest rates and maturity dates. This offering included Floating Rate Notes due 2019, 0.000% Notes due 2020, 0.250% Notes due 2022, and 1.000% Notes due 2027. The issuance was conducted under the company's existing shelf registration statement, indicating a strategic move to secure long-term funding. The company entered into underwriting and pricing agreements with several major financial institutions, including Barclays PLC, BNP Paribas, Goldman, Sachs & Co., and J.P. Morgan Securities plc, who acted as representatives for the underwriters. The details of these agreements and a related press release are filed as exhibits to this report, providing transparency into the transaction's structure and terms for investors. This action demonstrates Pfizer's proactive approach to managing its capital structure and funding needs.

Key Highlights

  • 1Pfizer Inc. priced a public offering of €4 billion in aggregate principal amount of notes on February 28, 2017.
  • 2The offering comprised multiple tranches: Floating Rate Notes due 2019, 0.000% Notes due 2020, 0.250% Notes due 2022, and 1.000% Notes due 2027.
  • 3The issuance was made under Pfizer's effective shelf registration statement (Form S-3) filed on March 2, 2015.
  • 4The company entered into underwriting and pricing agreements with a syndicate of underwriters.
  • 5Key underwriters included Barclays PLC, BNP Paribas, Goldman, Sachs & Co., and J.P. Morgan Securities plc.
  • 6This debt issuance indicates a strategy to secure significant funding and manage its capital structure.

Frequently Asked Questions

The primary purpose of this 8-K filing was to report on Pfizer Inc.'s pricing of a significant public offering of senior notes totaling €4 billion, conducted on February 28, 2017. It provides details about the various note series issued, their maturity dates, interest rates, and the involvement of underwriters.

Pfizer issued four series of notes: Floating Rate Notes due 2019, 0.000% Notes due 2020, 0.250% Notes due 2022, and 1.000% Notes due 2027. The total aggregate principal amount of the offering was €4 billion.

The offering involved several major financial institutions acting as underwriters. Barclays PLC, BNP Paribas, Goldman, Sachs & Co., and J.P. Morgan Securities plc served as the representatives of the several underwriters for this transaction.

This debt issuance allows Pfizer to raise substantial capital, which can be used for various corporate purposes such as funding operations, acquisitions, research and development, or repaying existing debt. The specific terms, including the interest rates and maturity dates, suggest a strategy to manage its cost of capital and debt maturity profile effectively.